BioCentury

8:00 AM GMT, Feb 8, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/5 cls
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Wedbush Y. Katherine Xu Upgrade Market outperform (from neutral) 1% $2.38
Xu cited increased confidence Achillion will partner ACH-1625, a selective inhibitor of HCV NS3 protease in Phase Ib testing. She said Phase Ib data showed that ACH-1625's potency as a single agent was at the high end of competitor HCV protease inhibitors in the clinic (see BioCentury, Jan. 18, 2010).
Acorda Therapeutics Inc. (NASDAQ:ACOR) Baird Christopher Raymond Downgrade Neutral (from market outperform) 9% $30.62
Deutsche Bank Mark Schoenebaum Price target Buy

Read the full 1275 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.